Does a genotype-guided de-escalation strategy improve cost-effectiveness and QALYs compared to standard DAPT in patients with acute coronary syndrome?
Patients with acute coronary syndrome (ACS)
Genotype-guided de-escalation strategy
Standard DAPT
Cost-effectiveness (costs and quality-adjusted life years [QALYs])
A genotype-guided de-escalation strategy for DAPT in ACS patients is cost-saving and improves quality-adjusted life years compared to standard DAPT.
A genotype-guided de-escalation strategy in patients with ACS was both cost-saving and yielded higher QALYs compared to standard DAPT, highlighting its potential for implementation in clinical practice. Trial registration: ClinicalTrials.gov identifier: NCT03823547.
Building similarity graph...
Analyzing shared references across papers
Loading...
Wout W. A. van den Broek
Interventional Cardiology
Jaouad Azzahhafi
Interventional Cardiology
Dean R.P.P. Chan Pin Yin
Interventional Cardiology
European Heart Journal - Cardiovascular Pharmacotherapy
University of Amsterdam
Erasmus MC
University Medical Center Utrecht
Building similarity graph...
Analyzing shared references across papers
Loading...
Broek et al. (Wed,) studied this question.
synapsesocial.com/papers/69a31653a60bae612d55e490 — DOI: https://doi.org/10.1093/ehjcvp/pvae087